USA flag logo/image

An Official Website of the United States Government

Microvascular Functional Imaging System

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43DK093192
Solicitation Year:
2011
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA10-050
Small Business Information
VISIONQUEST BIOMEDICAL, LLC
2501 Yale Blvd. SE ALBUQUERQUE, NM -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Microvascular Functional Imaging System
Agency: HHS
Contract: 1R43DK093192-01
Award Amount: $154,950.00
 

Abstract:

DESCRIPTION (provided by applicant): VisionQuest Biomedical and the University of New Mexico (UNM) Health Science Center have formed a team to implement and demonstrate a thermal-optical imaging system for detecting and quantifying neuronal and microvascular dysfunction associated with peripheral neuropathy. This team will develop and test the Microvascular1Functional Imaging System (MFIS), a device that can be easily adopted for both a clinical environment and a tele-screening setting. Diabetes afflicts an estimated 171 million people worldwide, including more than 24 million Americans. Diabetic patients are at risk for a wide array of complications including heart disease, kidney disease (nephropathy), ocular diseases (diabetic retinopathy), and peripheral neuropathy (diabetic foot). Two million diabetics will develop a foot ulcer during their lifetime. Foot ulcers are the main cause, 85 percent, of lower extremity amputation in patients with diabetes. Our MFIS device is aimed to show that differencesin the functional signals will reveal pre- clinical indications of peripheral neuropathy. There are three specific aims to be accomplished in Phase I. The first aim is to integrate, calibrate and test the MFIS device. The second aim is to use the MFIS toconduct a clinical study using subjects to be recruited at the University of New Mexico Endocrinology Clinic. In the third aim we will use advanced signal and image processing techniques, such as Independent Component Analysis (ICA), to extract low-level signals resulting from the functional response captured in thermal and spectral videos. Our commercialization strategy is to create two commercial instruments: One based in thermal imaging that can be used in a clinical setting for diagnosis of peripheral neuropathy, and a second low-cost device based on spectral imaging for screening purposes. PUBLIC HEALTH RELEVANCE: Peripheral neuropathy (diabetic foot) is a complication arising from diabetes that causes 82,000 lower extremity amputations in diabetic patients. Fifteen percent of diabetics will undergo amputation sometime in their lives. In this project, we will develop and test the Microvascular Functional Imaging System (MFIS), a thermal-optical imaging system for detecting and quantifying neuronal and microvascular dysfunction associated with peripheral neuropathy.

Principal Investigator:

Peter S. Soliz
505-508-1994
psoliz@visionquest-bio.com

Business Contact:

Peter Solix
505-508-1994
psoliz@visionquest-bio.com
Small Business Information at Submission:

VISIONQUEST BIOMEDICAL, LLC
2501 Yale Blvd. SE ALBUQUERQUE, NM -

EIN/Tax ID: 126186430
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: No